211 related articles for article (PubMed ID: 35987957)
21. Retrospective Comparative Study of Topical Interferon α2b Versus Mitomycin C for Primary Ocular Surface Squamous Neoplasia.
Kusumesh R; Ambastha A; Kumar S; Sinha BP; Imam N
Cornea; 2017 Mar; 36(3):327-331. PubMed ID: 28079688
[TBL] [Abstract][Full Text] [Related]
22. Management of Ocular Surface Squamous Neoplasia with Topical and Intralesional Interferon Alpha 2B in Mexicans.
Nava-Castañeda Á; Hernández-Orgaz J; Garnica-Hayashi L; Ansart A; Matus G; Tovilla-Canales JL
Nepal J Ophthalmol; 2018 Jul; 10(20):143-150. PubMed ID: 31056557
[TBL] [Abstract][Full Text] [Related]
23. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b.
Boehm MD; Huang AJ
Ophthalmology; 2004 Sep; 111(9):1755-61. PubMed ID: 15350333
[TBL] [Abstract][Full Text] [Related]
24. The Management of Ocular Surface Squamous Neoplasia (OSSN).
Yeoh CHY; Lee JJR; Lim BXH; Sundar G; Mehta JS; Chan ASY; Lim DKA; Watson SL; Honavar SG; Manotosh R; Lim CHL
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614155
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
Besley J; Pappalardo J; Lee GA; Hirst LW; Vincent SJ
Am J Ophthalmol; 2014 Feb; 157(2):287-293.e2. PubMed ID: 24184223
[TBL] [Abstract][Full Text] [Related]
26. Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.
Ashkenazy N; Karp CL; Wang G; Acosta CM; Galor A
Cornea; 2017 Apr; 36(4):506-510. PubMed ID: 28129301
[TBL] [Abstract][Full Text] [Related]
27. Amniotic Membrane Grafting for Ocular Surface Inflammation Following Topical Interferon Alpha 2b Therapy.
Shah SG; Mishra DK; Shah GY
J Interferon Cytokine Res; 2022 Mar; 42(3):137-139. PubMed ID: 35298286
[TBL] [Abstract][Full Text] [Related]
28. Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia.
Wotman KL; Chow L; Martabano B; Pezzanite LM; Dow S
Cancer Immunol Immunother; 2023 May; 72(5):1185-1198. PubMed ID: 36367558
[TBL] [Abstract][Full Text] [Related]
29. Topical medical therapies for ocular surface tumors.
Poothullil AM; Colby KA
Semin Ophthalmol; 2006; 21(3):161-9. PubMed ID: 16912014
[TBL] [Abstract][Full Text] [Related]
30. Changes in in vivo confocal microscopic findings of ocular surface squamous neoplasia during treatment with topical interferon alfa-2b.
Zarei-Ghanavati M; Mousavi E; Nabavi A; Latifi G; Mehrjardi HZ; Mohebbi M; Ghassemi H; Mirzaie F; Zare MA
Ocul Surf; 2018 Apr; 16(2):235-241. PubMed ID: 29306088
[TBL] [Abstract][Full Text] [Related]
31. The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size.
Vilaltella M; Huerva V
Arq Bras Oftalmol; 2021; 85(2):109-114. PubMed ID: 34431893
[TBL] [Abstract][Full Text] [Related]
32. Ocular surface squamous neoplasia: a standard of care survey.
Stone DU; Butt AL; Chodosh J
Cornea; 2005 Apr; 24(3):297-300. PubMed ID: 15778602
[TBL] [Abstract][Full Text] [Related]
33. Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma.
Tunc M; Erbilen E
Am J Ophthalmol; 2006 Oct; 142(4):673-5. PubMed ID: 17011863
[TBL] [Abstract][Full Text] [Related]
34. Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia.
Holcombe DJ; Lee GA
Am J Ophthalmol; 2006 Oct; 142(4):568-71. PubMed ID: 17011846
[TBL] [Abstract][Full Text] [Related]
35. Impression cytology following mitomycin C therapy for ocular surface squamous neoplasia.
McKelvie PA; Daniell M
Br J Ophthalmol; 2001 Sep; 85(9):1115-9. PubMed ID: 11520767
[TBL] [Abstract][Full Text] [Related]
36. Effect of Pegylated Interferon and Mitomycin C on Ocular Surface Squamous Neoplasia in Xeroderma Pigmentosum: A Case Series.
Dirar QS; Musalem HM; Al-Hazzaa SAF; Al Zoba AA; Almalki AA
Am J Case Rep; 2020 Apr; 21():e921301. PubMed ID: 32251268
[TBL] [Abstract][Full Text] [Related]
37. Topical mitomycin-C for treatment of partially-excised ocular surface squamous neoplasia.
Rahimi F; Alipour F; Ghazizadeh Hashemi H; Hashemian MN; Mehrdad R
Arch Iran Med; 2009 Jan; 12(1):55-9. PubMed ID: 19111031
[TBL] [Abstract][Full Text] [Related]
38. Interferon Alfa 2b for Ocular Surface Squamous Neoplasia: Factors Influencing the Treatment Response.
Kaliki S; Bejjanki KM; Desai A; Mohamed A
Semin Ophthalmol; 2019; 34(7-8):465-472. PubMed ID: 31370766
[TBL] [Abstract][Full Text] [Related]
39. Ocular surface squamous neoplasia: management and outcomes.
Hӧllhumer R; Williams S; Michelow P
Eye (Lond); 2021 Jun; 35(6):1562-1573. PubMed ID: 33564137
[TBL] [Abstract][Full Text] [Related]
40. Optical coherence tomography angiography in the evaluation of vascular patterns of ocular surface squamous neoplasia during topical medical treatment.
Theotoka D; Liu Z; Wall S; Galor A; Al Bayyat GJ; Feuer W; Jianhua W; Karp CL
Ocul Surf; 2022 Jul; 25():8-18. PubMed ID: 35358712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
